Case Report

Endometriosis in a Renal Transplant Recipient

Rakesh Madhyastha, Ammar Abdulbaki, Sudeendra Gupta and Nizar Attallah*

Department of Nephrology, Medical Subspecialties Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE

ABSTRACT

Hormonal abnormalities that are associated with advanced kidney failure normally reverses after kidney transplantation. This usually helps to normalize menstrual cycles for female patients and helps improve fertility. Post-transplant gynaecological disorders are under-reported in general. We present a patient who developed endometriosis after second kidney transplant. She was treated with surgery followed by hormonal therapy. We discuss the pathophysiology of endometriosis and possible relation to the immune system.

Background

Organ transplantation is now a universally accepted treatment for organ failure. Kidney Transplantation improves end-stage renal disease patients’ survival and quality of life in comparison with dialysis. Hypothalamic pituitary axis normalizes life post-transplant. Some of the well-known gynaecological complications post-transplant are prolonged and profuse menstruation and inter-menstrual bleeding or spotting. Reports also suggest a higher rate of endometrial hyperplasia (without atypia) in renal allograft recipients [1, 2]. After successful renal transplantation, cyclical ovarian function and fertility are often restored.

Case History

We present a case of a 33-year-old unmarried female who underwent a second living unrelated kidney transplant in September 2017 with immediate graft function and uneventful post-operative recovery. Her first transplant was a combined deceased donor kidney and heart transplant that was done in December 2014 and complicated with loss of renal allograft from antibody-mediated rejection leading to return to dialysis in May 2017 while the heart transplant continued to function well. Her original heart disease was idiopathic Myocarditis while her original kidney disease was thought to be focal segmental glomerulosclerosis (FSGS) that got worse with worsening heart failure.

She was treated aggressively for the antibody-mediated rejection, but despite that allograft dysfunction and proteinuria continued to progress. Following her second kidney transplant, she was placed on a triple immunosuppressive regimen of Tacrolimus, Mycophenolate mofetil, and Prednisolone. Serum creatinine settled at 60-80 micromole/L and proteinuria disappeared.

In February 2018 she presented to the clinic with right lower quadrant pain started in December 2017, waxing, and waning in character and gradually worsening to the point where she was unable to sit, stand, or sleep without having pelvic fullness and pain as well as bloating. Her menstrual cycles were regular till early January 2018 when she started to have bleeding twice a month.

On further questioning, she admitted to having always had painful periods. No family members with known endometriosis. She denied any family history of ovarian, colorectal or breast malignancy. MRI scan was done and revealed a right 13 cm complex, septated, hemorrhagic debris-filled ovarian cyst (Figures 1A & 1B). The patient was taken up for surgical removal of the cyst and argon laser coagulation of endometrial implants. Intra-operative findings revealed grade 3 endometriosis involving bilateral fallopian tubes and uterus had dense posterior adhesions to the rectum and right pelvic sidewall and had anterior adhesions to bladder highly suggestive of endometriosis. The patient has normal postoperative renal recovery with no evidence of acute kidney
Endometriosis in a Renal Transplant Recipient

injury. Post-surgery, the patient was maintained on Medoxy-progesterone acetate every 3 months. She is currently asymptomatic with stable kidney function and no proteinuria.

Figure 1: MRI pelvis with contrast in A) axial view and B) sagittal view showing large midline pelvis mass reported to be arising from the right ovary containing multiple septations which does not enhance clearly. It contains T2 dark and T1 bright non-enhancing debris. The mass is diffusely T1 bright, contains dependent debris which is more T1 bright than the remainder of the mass.

Discussion

Endometriosis is an estrogen-dependent inflammatory disease, which affects 6%–10% of women of reproductive age [3-5]. This disease is defined as the presence of endometrial glandular and stromal tissues in sites outside the uterine cavity, primarily on ovaries and the pelvic peritoneum [6]. The Association of CKD with endometriosis is not well studied. A few case reports of obstructive uropathy showed an association with endometriosis [7-10]. A retrospective analysis on 27,973 patients revealed endometriosis to be inversely proportional to CKD (crude HR 0.65, 95% CI 0.53–0.81, p < 0.001) [11]. However, in another similar study designed to determine the prevalence of organic causes of abnormal uterine bleeding in this group of patients exposed to unopposed estrogen, only 2 of 8 patients (25%) with chronic renal failure had endometrial lesions while 44 of 131 patients (33.6%) had either endometrial polyp, simple or atypical endometrial hyperplasia or endometrial carcinoma (p > 0.05) [12].

Patients with secretory and atrophic endometrium were excluded from this study. Uremia in CKD may have no role to play in endometrial responsiveness to estrogen. Despite the substantial effect that endometriosis has on women, their families and the economy, public and professional awareness of the disorder remains poor [13]. The true prevalence of endometriosis is uncertain, however, because the definitive diagnosis requires surgical visualization. The prevalence ranges from 2 to 11% among asymptomatic women, 5 to 50% among infertile women, and 5 to 21% among women hospitalized for pelvic pain.

Endometriotic cells and tissue elicit a localized immune and inflammatory response with the production of cytokines, chemokines, and prostaglandins. The dysfunction of the innate and adaptive immune system is evident but it is unclear whether immune dysfunction initiates endometriosis or is a pathophysiological hallmark of the disorder [14]. However, in general, it seems there is a local and sterile inflammation that occurs in the peritoneal cavity and there is substantial evidence that immunological factors and angiogenesis play a decisive role in the pathogenesis of the disease. Peritoneal macrophages also play a pivotal role in the intraabdominal environment [15]. Theoretically, immunosuppressive therapy would halt those processes and that is why probably it is uncommon to see patients with endometriosis after transplantation. Other mechanisms contribute to the development of endometriosis. That is probably why it happened in this immunocompromised patient. On the other hand, in our literature search, we found only animal studies done on the effects of immunosuppression on development and progression of endometriosis and this was done on baboons and the result was largely inconclusive [16, 17].

Conclusion

In this case report, we bring forward the importance of gynaecological complications following renal transplant which arises due to normalizing hormonal balance after transplant. Gynaecological complications following transplant are under-reported. Our case report is unique in this aspect as this is the first case of post-transplant endometriosis ever to be reported thus far. Theoretically, the prevalence of endometriosis must have been mitigated in a transplant patient however this case report shows that more studies need to be done in this front.

Consent

Informed consent was obtained from the patient prior to writing this report.

Conflicts of Interest

None.

REFERENCES

3. Lee WL, Chang WH, Wang KC, Guo CY, Chou YJ et al. (2015) The risk of epithelial ovarian cancer of women with endometriosis may be varied greatly if diagnostic criteria are different: A nationwide population-based cohort study. *Medicine (Baltimore)* 94: e1633. [Crossref]


